KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 80 filers reported holding KEROS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $154,329 | -31.0% | 3,377 | -0.0% | 0.00% | 0.0% |
| Q1 2024 | $223,624 | +82.8% | 3,378 | +9.8% | 0.00% | – |
| Q4 2023 | $122,342 | +23.2% | 3,077 | -1.2% | 0.00% | – |
| Q3 2023 | $99,274 | -23.3% | 3,114 | -3.3% | 0.00% | -100.0% |
| Q2 2023 | $129,380 | +472.8% | 3,220 | +508.7% | 0.00% | – |
| Q1 2023 | $22,588 | +14.5% | 529 | +28.7% | 0.00% | – |
| Q4 2022 | $19,736 | +9.6% | 411 | -16.1% | 0.00% | – |
| Q3 2022 | $18,000 | +28.6% | 490 | 0.0% | 0.00% | – |
| Q2 2022 | $14,000 | -51.7% | 490 | -7.5% | 0.00% | – |
| Q1 2022 | $29,000 | -37.0% | 530 | -32.4% | 0.00% | – |
| Q4 2021 | $46,000 | +39.4% | 784 | -5.1% | 0.00% | – |
| Q3 2021 | $33,000 | -8.3% | 826 | -1.3% | 0.00% | – |
| Q2 2021 | $36,000 | -28.0% | 837 | +3.3% | 0.00% | – |
| Q1 2021 | $50,000 | – | 810 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
| First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
| Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
| Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
| Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
| Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
| CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
| Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
| Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
| Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |